| 词条 | Doravirine |
| 释义 |
| drug_name = | IUPAC_name = 3-Chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydro-3-pyridinyl}oxy)benzonitrile | image = Doravirine structure.svg | alt = | caption = | tradename = Pifeltro | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Oral[1] | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1338225-97-0 | CAS_supplemental = | ATCvet = | ATC_prefix = J05 | ATC_suffix = AG06 | ATC_supplemental = | PubChem = 58460047 | IUPHAR_ligand = | DrugBank = DB12301 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = | ChemSpiderID = 28424197 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 913P6LK81M | KEGG = D10624 | ChEMBL = 2364608 | PDB_ligand = 2KW | synonyms = MK-1439 | C = 17 | H = 11 | Cl = 1 | F = 3 | N = 5 | O = 3 | molecular_weight = 425.75 g/mol | smiles = Cn1c(n[nH]c1=O)Cn2ccc(c(c2=O)Oc3cc(cc(c3)Cl)C#N)C(F)(F)F | StdInChI = 1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28) | StdInChIKey = ZIAOVIPSKUPPQW-UHFFFAOYSA-N }}Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor developed by Merck & Co. for use in the treatment of HIV/AIDS. In August 2018, the FDA approved doravine under the product name Pifeltro, and in a combination tablet, doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo).[2] References1. ^{{cite web|last1=Collins|first1=Simon|last2=Horn|first2=Tim|title=The Antiretroviral Pipeline.|url=http://www.pipelinereport.org/sites/g/files/g575521/f/201509/ARV.pdf|website=Pipeline Report|accessdate=6 December 2015|page=10|deadurl=yes|archiveurl=https://web.archive.org/web/20160311235843/http://www.pipelinereport.org/sites/g/files/g575521/f/201509/ARV.pdf|archivedate=11 March 2016|df=}} {{Antiretroviral drug}}{{antiinfective-drug-stub}}2. ^FDA Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients 6 : Antiretroviral drugs|Nitriles|Trifluoromethyl compounds|Nitrogen heterocycles|Chloroarenes|Phenol ethers |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。